PARP inhibitors
Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development
The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men
Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.
Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.